Skip to content
Screener

Interest Income at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$6.25M+16.0%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$7.12M+0.1%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$2.79M+17.0%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$3.56M-50.4%

Other financials

Income statement

See full
Revenue-
Operating income-$505.1M-90.8%
Net income-$644.4M-160%
EPS (diluted)-$3.06-134%

Balance sheet

See full
Cash & equivalents$815.4M+103%
Total debt$154.5M+16.3%
Total equity$2.6B+39.7%
Total assets$4.3B+77.9%

Cash flow

See full
Operating cash flow-$387.3M-74.7%
CapEx$2.3M-69.3%
Free cash flow-$389.6M-70.0%

Valuation

See full
Market cap$41.95B+514%
Enterprise value$41.28B+529%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp
FCF margin-74,273.9%-75,457pp

Returns & leverage

See full
Return on equity-79.1%+182pp
Debt / equity0.1×0.0×
Current ratio11.4×-0.4×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Revolution Medicines, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:10 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335104
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total operating expenses505,132264,714950,354505,474
Loss from operations(505,132)(264,714)(950,354)(505,474)
Non-operating income (expense), net:
Interest income35,57922,40455,08747,319
Interest expense(23,781)(867)(35,978)(867)
Change in fair value of warrant liability(151,031)(4,578)(166,819)(2,139)
Other expense, net(6)(32)(123)(42)
Total non-operating income (expense), net(139,239)16,927(147,833)44,271

Item 1. Financial Statements.

FAQ

What is Revolution Medicines, Inc.'s interest income?
Revolution Medicines, Inc. (RVMD) reported interest income of $35.58M in Q2 2026.
How has Revolution Medicines, Inc.'s interest income changed year-over-year?
Revolution Medicines, Inc.'s interest income increased by 58.8% year-over-year, from $22.4M to $35.58M.
What is the long-term trend for Revolution Medicines, Inc.'s interest income?
Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s interest income has grown at a 214.3% compound annual growth rate (CAGR), from $929K to $90.69M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Revolution Medicines, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude